Beam Therapeutics is trading 6.2% down at $27.83 in pre-market, with available company materials not establishing that the positive update caused the decline.
- It closed at $29.66 on September 4, 2026.
- The company presented updated BEAM-302 data at the European Respiratory Society Congress and scheduled a 7:00 a.m. ET investor webcast.
- Results highlighted durability and potential one-time treatment benefits; broader sentiment is only modestly weaker.